v3.20.2
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Cash flows from operating activities:      
Net loss from continuing operations $ (5,729,780) $ (904,156)  
Net gain from discontinued operations 57,709  
Adjustments to reconcile net loss to net cash used in operations      
Non-cash interest expense 3,688,762 331,682  
Amortization and depreciation 11,081 11,216  
Loss (Gain) on fair value change of derivatives 1,534,173 (47,610)  
Loss (Gain) on extinguishment of debt 195,542 (136,675)  
Stock compensation expense 54,033 395,720 $ 410,370
Gain on termination of license (86,856)  
Changes in operating assets and liabilities:      
Accounts receivable (16,438)  
Prepaid expenses 1,624 10,610  
Accounts payable and accrued expenses 124,901 91,624  
Accounts payable and accrued expenses, related parties (14,700) (22,690)  
Net cash used in operating activities-continuing operations (221,253) (286,717)  
Net cash provided by operating activities-discontinued operations 89,326  
Net cash used in operating activities (131,927) (286,717)  
Cash flows from investing activities:      
Net cash provided by investing activities  
Cash flows from financing activities:      
Redemption of preferred stock (50,000)  
Proceeds from sale of common stock 80,000  
Proceeds from issuances of convertible notes payable 207,000 295,650  
Payments of principal of convertible note payable and notes payable (84,000)  
Net cash provided by financing activities 157,000 291,650  
Effects of exchange rate on cash (741) 187  
Net decrease in cash 24,332 5,120  
Cash, Beginning of period 10,877 50,903 50,903
Cash, End of period 35,209 56,023 $ 10,877
Supplemental disclosure of cash flow information:      
Cash paid for interest 47,737 6,755  
Cash paid for income taxes  
Schedule of non-cash Investing or Financing Activity:      
Original issue discount included in convertible notes payable 286,250 47,350  
Default penalties added to convertible notes payable 272,400  
Issuance of common stock upon convertible note and accrued interest conversion 181,320 51,750  
Reclassification of notes payable to convertible notes payable 330,000  
Carrying value of assets and liabilities at termination of license with Spinal Resources, Inc.      
Inventory 374,500  
Implant instruments, net 350,825  
Patent rights, net 2,714,204  
Goodwill 2,002,314  
License fee payable (1,234,089)  
Present value of option to buy SRI (2,899,420)  
Common stock payable (245,000)    
Iberia Note (447,153)  
Equity line payable (45,359)  
Note issued for inventory and instruments (640,699)  
Accrued interest (16,979)  
Gain on termination $ 86,856  

Source